Portfolio
Specialty Pharmaceuticals
| Great Point Company | Description | Invested | Status |
|
APT Pharmaceuticals, Inc. Burlingame, CA View Web Site 
|
APT is a leading specialty pharmaceuticals business focusing on rare lung diseases. APT is developing Pulminiq, a proprietary formulation of inhaled cyclosporine, for prevention of chronic rejection and death in lung transplant patients. Pulminiq is entering a pivotal Phase 3 trial in approximately 150 patients at leading lung transplant centers worldwide. APT is also developing other pulmonary products. | 2007 | Private |
|
Biodel, Inc. Danbury, CT View Web Site 
|
Biodel's first product is a rapid acting injectable insulin called Viaject™. Viaject™ is designed to speed the delivery of insulin into the blood and will compete in the multi-billion dollar rapid acting insulin market. The Company has been financed with growth equity from Great Point Partners. | 2006 | IPO 2007 |